randomized subjects, 100 subjects were followed for 24 months and 73 subjects were followed for 36 months. Follow-up on all subjects is ongoing.
added in 6 eyes) and 15.3 mmHg in travoprost eyes (with a second medication added in 11 eyes). In the subset of eyes that did not require additional medical therapy, mean IOP was 14.5 mmHg and 15.7 mmHg in the respective groups. Ninety-one percent of stent eyes had 3-year IOP B18 mmHg without additional therapy (62% B 15 mmHg) and 79% of travoprost eyes had 3-year IOP B18 mmHg (21% B 15 mmHg). Safety was favorable in both groups.
Conclusions: In this prospective, randomized comparison of subjects with newly diagnosed POAG naïve to therapy, substantial IOP reduction with a favorable low complication rate was shown through 3 years after either 2 trabecular stents implanted as the sole procedure or topical travoprost therapy. These data suggest 2-stent implantation may be a viable initial treatment option comparable to topical prostaglandin in newly diagnosed POAG patients.
INTRODUCTION
Traditionally, treatment for newly diagnosed open-angle glaucoma (OAG) has started with topical ocular hypotensive medical therapy, followed by laser trabeculoplasty. These approaches have a lower risk profile than filtering or drainage device surgery. Further, these modalities preserve ocular tissues in case more invasive surgery is eventually required.
Despite these advantages, the efficacy of medical and laser therapy is limited. Various factors may hinder the proper use of topical medications, such as side effects (e.g., ocular hyperemia, iris hyperchromia, and periorbital atrophy), cost, intolerance to topical medications, and difficulty with drop instillation [1, 2] . In addition, patient adherence to medical therapy is frequently documented to be low [3] [4] [5] [6] . In one study of 28,741 patients are naïve to glaucoma therapy, for example, 70% of patients discontinued their therapy after 1 year [3] . Such non-compliance limits the actual vs. expected effect of medical therapy and can increase the risk of disease progression, cost to patients, and cost to providers [7] . Laser procedures do not share the same challenges as topical medications, but their efficacy may be limited by short-term inflammation and long-term attrition [8] . ClinicalTrials.gov registration number for this study is NCT01443988 [26] .
One-hundred qualified subjects were to be randomized in a The iStent device and implantation technique have been described in detail in previous work [12] . In brief, this single-piece, titanium, heparin-coated device has an L-shaped structure with a snorkel (inlet) on the short side which resides in the anterior chamber. The inlet opens to the half-pipe body which resides in Schlemm's canal. The stent is 
RESULTS

Subject Accountability, Demographics, and Pre-Study Parameters
A total of 101 subjects (101 POAG, 1 PEX) completed the screening examination and were randomized to treatment with either two stents or with travoprost. To eliminate different diagnoses as a potential confounder, the one subject with PEX was excluded from the current analysis. Of the 101 subjects with POAG, 100 subjects completed follow-up through month 24 and 73 subjects completed follow-up through month 36.
Demographics and pre-treatment parameters are shown in Table 1 . The stent and travoprost groups were similar in age (64.5 ± 11.1 vs.
62.0 ± 11.3 years, respectively), screening IOP (25.5 ± 2.5 vs. 25.1 ± 4.6 mmHg), C:D ratio (0.7 ± 0.2 vs. 0.6 ± 0.1), visual field, central corneal thickness, and BCVA. There were fewer males in the 2-stent group (25/54 or 46%) than in the medication group (32/47 or 68%). All subjects were Caucasian.
Efficacy
Subjects experienced notable reduction of IOP following implantation of two iStent trabecular micro-bypass devices or administration of topical travoprost (Fig. 1) (Fig. 2) .
Proportional analyses showed that 94%, 90%, and 91% of stent-treated eyes had IOP B18 mmHg without the need for postoperative medication at 1, 2 and 3 years, respectively, while 89%, 87% and 79% of eyes in the travoprost group achieved IOP B18 mmHg at these timepoints without requiring additional medical therapy. The majority (62%) of stent eyes maintained IOP B15 mmHg through 3 years, while a decreasing percentage (21%) of travoprost eyes maintained IOP B15 mmHg over the 3-year follow-up period (Fig. 3) .
Safety
Safety was favorable in both groups. Two complications were reported during stent insertion in the surgery group, both of which were attributed to subject movement during surgery: one of these subjects had hyphema which resolved by day 1 and one subject had a small iridodialysis which resulted in no postoperative ocular sequelae. No other operative complications were reported.
In general, BCVA was stable over time for both groups (Fig. 4) . Progression of cataract over the 3-year follow-up period was reported in 11 eyes (20%) in the stent group and 8 eyes (17%) in the travoprost group. Of these, cataract surgery was performed in 6 eyes (5 in stent group and 1 in travoprost group), with last reported BCVA of 20/40 or better in these operated eyes. In the remaining non-operated subjects, three-year BCVA was 20/40 or better in 6 eyes (2 in stent group and 4 in med group), iStent implantation as initial therapy may offer several benefits over topical medications, whose utility may be limited by issues such as side effects and patient compliance [1] [2] [3] [4] [5] [6] [7] [27] [28] [29] [30] . Furthermore, the cost of both brand-name and generic medications places a considerable financial burden on the newly diagnosed glaucoma patient [31] , thus making a longstanding surgical solution even more appealing. This may be particularly important in glaucoma patients, the majority of whom have at least one additional chronic condition requiring medication [32] .
In this study, the IOP decrease in the travoprost group was greater than the 25-35% IOP reductions reported in prior work [33] [34] [35] .
This may be due to medication-naïve eyes, high compliance due to study participation, and/or regression to the mean. The greater IOP phenomenon which has been reported previously in both treated and treatment-naïve glaucoma patients [35, 36] .
There are several limitations to this study. Given the surgical vs. medical therapy study design, neither subjects nor clinicians were masked to treatment. Diurnal measurements of IOP were not performed. A pre-treatment grading of the crystalline lens was not used, and guidelines for when to perform cataract surgery were not standardized. Future work could incorporate such measures to address these study limitations, and also could encompass postoperative follow-up past 3 years. In addition, future analyses may examine the long-term cost effectiveness of 
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